RxDoctor Payments Data

James Muth

Clinical Cardiac Electrophysiology · Lawrenceburg, INNPI 1750586483

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (43.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Biotronik Inc. at 47.5% of the total. Reporting peaked in 2019 at $24,205 and has fallen 81.5% since, to $4,484 in 2025.

$48,364in general payments, 2019–2025

Across 312 payments — averaging $155.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$23K
  • Medtronic$12K
  • Boston Scientific$7K
  • Medical Device Business Services, Inc.$1K
  • Biosense Webster, Inc.$1K
  • Abbott$955
  • plus $3K from 27 others

What the payments were for

  • Speaking & faculty fees$13,30027%
  • Travel & lodging$21,02643%
  • Food & beverage$14,00729%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,364 in reported general payments places this provider in the 75th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$181,370
Medicare patients
409
Services billed
1,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$189,510
XareltoRivaroxaban11$18,499
Midodrine Hcl21$2,572
Flecainide Acetate47$1,958
Amiodarone Hcl102$1,756
Metoprolol Succinate145$1,692
SotalolSotalol Hcl45$1,035
Diltiazem 24hr Er (Cd)Diltiazem Hcl37$546
Metoprolol Tartrate44$337
Amlodipine Besylate31$192
Losartan Potassium26$185
Pantoprazole Sodium21$166
Lisinopril25$162
Rosuvastatin Calcium13$152
Bisoprolol Fumarate15$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$135$189,510194 claims
Johnson & JohnsonXarelto$89$18,49911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Lawrenceburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →